ARS Pharmaceuticals, Inc.

Contributing Author

Recent Articles by ARS Pharmaceuticals, Inc.

Jan-21	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use SPRY GlobeNewswire
Dec-29	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
Nov-26	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference SPRY GlobeNewswire
Nov-10	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) SPRY GlobeNewswire
Nov-04	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) SPRY GlobeNewswire
Nov-03	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting SPRY GlobeNewswire
Nov-03	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results SPRY GlobeNewswire
Nov-03	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting SPRY GlobeNewswire
Oct-08	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) SPRY GlobeNewswire
Sep-29	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy SPRY GlobeNewswire
Sep-19	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
Sep-08	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis SPRY GlobeNewswire
Aug-28	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SPRY GlobeNewswire
Aug-13	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) SPRY GlobeNewswire
Aug-04	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results SPRY GlobeNewswire
Jul-18	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) SPRY GlobeNewswire
May-27	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SPRY GlobeNewswire
May-14	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) SPRY GlobeNewswire
May-07	ARS Pharmaceuticals' neffy (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms SPRY GlobeNewswire
May-05	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results SPRY GlobeNewswire
May-02	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians SPRY GlobeNewswire

ARS Pharmaceuticals, Inc.

Recent Articles by ARS Pharmaceuticals, Inc.

Upgrade your FINVIZ experience